Astrazeneca Pharma India Ltd

Panchal is set to transition to a global role within the AstraZeneca Group, based in Gaithersburg, Maryland, US. The board acknowledged his resignation and placed on record its appreciation for his contributions during his tenure. Following the recommendation of the nomination and remuneration committee, the board has approved the appointment of Praveen Rao Akkinepally as the new MD. He will take charge from 1 July 2025, for a term of three years. Akkinepally is a senior commercial leader with over two decades of experience across the US, global markets, and India, particularly in oncology and biopharmaceuticals. He has led several brand launches and driven global commercial strategies at AstraZeneca. His previous role as oncology business unit head for India saw significant growth in the company's market presence and a series of successful oncology product launches. Beyond his corporate achievements, he has contributed to healthcare policy through his work with the Federation of Indian Chambers of Commerce and Industry's cancer round tables. Akkinepally holds an MBA from the University of Michigan's Ross School of Business and a master's in public health from Johns Hopkins University. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries. The company's standalone net profit rose 47.54% to Rs 58.25 crore, while revenue from operations rose 25.39% to Rs 480.48 crore in Q4 March 2025 over Q4 March 2024. Powered by Capital Market - Live

Niva Bupa Health Insurance Company Ltd, Indian Overseas Bank, Sterling & Wilson Renewable Energy Ltd, Capri Global Capital Ltd are among the other stocks to see a surge in volumes on NSE today, 02 June 2025.Astrazeneca Pharma India Ltd registered volume of 7.73 lakh shares by 14:14 IST on NSE, a 62.2 fold spurt over two-week average daily volume of 12432 shares. The stock rose 12.66% to Rs.8,981.00. Volumes stood at 15250 shares in the last session.Niva Bupa Health Insurance Company Ltd saw volume of 1498.24 lakh shares by 14:14 IST on NSE, a 26.47 fold spurt over two-week average daily volume of 56.61 lakh shares. The stock dropped 9.76% to Rs.83.28. Volumes stood at 59.61 lakh shares in the last session.Indian Overseas Bank notched up volume of 800.38 lakh shares by 14:14 IST on NSE, a 7.74 fold spurt over two-week average daily volume of 103.44 lakh shares. The stock rose 4.89% to Rs.41.79. Volumes stood at 303.39 lakh shares in the last session.Sterling & Wilson Renewable Energy Ltd recorded volume of 84.57 lakh shares by 14:14 IST on NSE, a 7.49 times surge over two-week average daily volume of 11.30 lakh shares. The stock gained 9.22% to Rs.308.45. Volumes stood at 8.71 lakh shares in the last session.Capri Global Capital Ltd registered volume of 38.42 lakh shares by 14:14 IST on NSE, a 6.49 fold spurt over two-week average daily volume of 5.92 lakh shares. The stock rose 3.01% to Rs.156.26. Volumes stood at 12.3 lakh shares in the last session.Powered by Capital Market - Live

Sun Pharma Advanced Research Company Ltd, Bank of Maharashtra, Reliance Power Ltd and Genus Power Infrastructures Ltd are among the other gainers in the BSE's 'A' group today, 02 June 2025.Astrazeneca Pharma India Ltd spiked 11.17% to Rs 8855 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 24613 shares were traded on the counter so far as against the average daily volumes of 920 shares in the past one month. Sun Pharma Advanced Research Company Ltd soared 10.07% to Rs 203.8. The stock was the second biggest gainer in 'A' group. On the BSE, 3.28 lakh shares were traded on the counter so far as against the average daily volumes of 69764 shares in the past one month. Bank of Maharashtra surged 6.93% to Rs 57.73. The stock was the third biggest gainer in 'A' group. On the BSE, 52.36 lakh shares were traded on the counter so far as against the average daily volumes of 12.82 lakh shares in the past one month. Reliance Power Ltd rose 6.09% to Rs 61.7. The stock was the fourth biggest gainer in 'A' group. On the BSE, 375.97 lakh shares were traded on the counter so far as against the average daily volumes of 158.73 lakh shares in the past one month. Genus Power Infrastructures Ltd advanced 5.94% to Rs 418.45. The stock was the fifth biggest gainer in 'A' group. On the BSE, 4.95 lakh shares were traded on the counter so far as against the average daily volumes of 1.27 lakh shares in the past one month. Powered by Capital Market - Live

Max Healthcare Institute Ltd, Godrej Consumer Products Ltd, Mphasis Ltd, Indraprastha Gas Ltd are among the other stocks to see a surge in volumes on BSE today, 02 June 2025.Astrazeneca Pharma India Ltd recorded volume of 20063 shares by 10:46 IST on BSE, a 24.47 times surge over two-week average daily volume of 820 shares. The stock gained 11.18% to Rs.8,855.50. Volumes stood at 1496 shares in the last session.Max Healthcare Institute Ltd saw volume of 11.56 lakh shares by 10:46 IST on BSE, a 11.71 fold spurt over two-week average daily volume of 98752 shares. The stock increased 2.21% to Rs.1,149.85. Volumes stood at 19937 shares in the last session.Godrej Consumer Products Ltd registered volume of 58939 shares by 10:46 IST on BSE, a 8.21 fold spurt over two-week average daily volume of 7182 shares. The stock rose 2.53% to Rs.1,262.60. Volumes stood at 2591 shares in the last session.Mphasis Ltd saw volume of 25982 shares by 10:46 IST on BSE, a 4.14 fold spurt over two-week average daily volume of 6282 shares. The stock dropped 3.11% to Rs.2,480.00. Volumes stood at 4930 shares in the last session.Indraprastha Gas Ltd registered volume of 3.58 lakh shares by 10:46 IST on BSE, a 3.96 fold spurt over two-week average daily volume of 90342 shares. The stock rose 2.05% to Rs.211.10. Volumes stood at 84867 shares in the last session.Powered by Capital Market - Live

Profit before tax (PBT) stood at Rs 78.47 crore in Q4 FY25, up 44.35% year-on-year, and up 86.74% quarter-on-quarter. Total expenses rose 22.22% to Rs 412.48 crore in Q4FY25 over Q4FY24. During the quarter, cost of materials consumed stood at Rs 94.25 crore (up 180.34% YoY) while employee benefits expense was at Rs 66.07 crore (up 13.95% YoY). The company's net profit surged 88.82% while net sales rose 9.13% in Q4 March 2025 over Q3 December 2024. For the full year FY25, revenue from operations rose 32.48% to Rs 1,716.29 crore, while net profit fell 28.34% to Rs 115.74 crore. PBT fell 28.78% to Rs 156.36 crore compared to FY24. The company's standalone net cash from operating activities stood at Rs 65.36 crore in FY25, as against Rs 27.87 crore in FY24. Dr. Sanjeev Panchal, country president & managing director of the company, said, Our company delivered strong growth in Financial Year 2024-25 by launching innovative medicines in India, giving us momentum into 2025 and beyond. We are pleased to share that our company has, for the first time, crossed the INR 1,700 crore mark ($200 million). The board recommended dividend of Rs 32 per equity share for FY25. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries. Powered by Capital Market - Live

Astrazeneca Pharma India Ltd gained 7.28% today to trade at Rs 8545.4. The BSE Healthcare index is up 0.34% to quote at 42749.54. The index is up 1.8 % over last one month. Among the other constituents of the index, Orchid Pharma Ltd increased 3.84% and Cohance Lifesciences Ltd added 1.94% on the day. The BSE Healthcare index went up 22.53 % over last one year compared to the 9.81% surge in benchmark SENSEX. Astrazeneca Pharma India Ltd has added 2.1% over last one month compared to 1.8% gain in BSE Healthcare index and 0.88% rise in the SENSEX. On the BSE, 1001 shares were traded in the counter so far compared with average daily volumes of 913 shares in the past one month. The stock hit a record high of Rs 9199 on 24 Apr 2025. The stock hit a 52-week low of Rs 5415.55 on 04 Jun 2024.Powered by Capital Market - Live

Net profit of Astrazeneca Pharma India rose 47.54% to Rs 58.25 crore in the quarter ended March 2025 as against Rs 39.48 crore during the previous quarter ended March 2024. Sales rose 25.39% to Rs 480.48 crore in the quarter ended March 2025 as against Rs 383.20 crore during the previous quarter ended March 2024. For the full year,net profit declined 28.34% to Rs 115.74 crore in the year ended March 2025 as against Rs 161.51 crore during the previous year ended March 2024. Sales rose 32.48% to Rs 1716.29 crore in the year ended March 2025 as against Rs 1295.53 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales480.48383.20 25 1716.291295.53 32 OPM %17.9812.89 -14.8014.24 - PBDT101.8458.12 75 293.14218.05 34 PBT84.1554.36 55 253.15203.11 25 NP58.2539.48 48 115.74161.51 -28 Powered by Capital Market - Live

Astrazeneca Pharma India announced that the Board of Directors of the Company at its meeting held on 30 May 2025, inter alia, have recommended the final dividend of Rs 32 per equity Share (i.e. 1600%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). This approval paves the way for the marketing of Benralizumab Solution for Injection (brand name Fasenra) in India for the specified additional indication, subject to the receipt of any related statutory approvals, if required. AstraZeneca Pharma India is engaged in the business of manufacture, distribution, and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. The company's standalone net profit surged to Rs 54.68 crore in Q3 FY25 as compared with Rs 15.80 crore in Q3 FY24. Revenue from operations jumped 44% to Rs 440.29 crore in Q3 FY25 as compared with Rs 305.79 crore in Q3 FY24. The scrip shed 0.10% to end at Rs 7,910.55 on the BSE. Powered by Capital Market - Live

AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Benralizumab 30 mg/ml Solution for Injection (Brand name: Fasenra) for an additional indication. Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). The receipt of this permission paves way for the marketing of Benralizumab 30 mg/ml Solution for Injection (Brand name: Fasenra) in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.Powered by Capital Market - Live